ClinicalTrials.gg
CompletedNCT06836557Updated Oct 19, 2026

Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis

A Phase 3 interventional study of Tradipitant in Idiopathic Gastroparesis, Diabetic Gastroparesis and Gastroparesis, sponsored by Vanda Pharmaceuticals. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

Updated Oct 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Gastroparesis with a site in Belgium — none open to participants now, none under way, none of them phase 3. Gastroparesis · Belgium.

Enrollment
16th of 18
17 · median 84
Started
2024
with 1 other
Phase 3
5 of 18
none open now
Registered
18th of 18
by date

Among the 18 studies in Gastroparesis with a site in Belgium, this one is the 16th largest by enrollment, is one of 2 that started in 2024, is one of 5 in phase 3, and was the 18th registered.

Gastroparesis

323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.

Browse Gastroparesis studies →

Open to participants now

None of the 18 studies in Gastroparesis with a site in Belgium is open now. The open studies under Gastroparesis, anywhere →

Who these studies take

Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies in Gastroparesis with a site in Belgium as a file.
02

Study summary

This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.

03

Conditions studied

  • Idiopathic Gastroparesis
  • Diabetic Gastroparesis
  • Gastroparesis

Keywords

  • gastroparesis
  • idiopathic
  • diabetic
  • tradipitant
  • nausea
  • vomiting
  • stomach
  • motility
  • functional
  • NK-1 antagonist
  • neurokinin 1 receptor
  • substance p
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with gastroparesis
  • Demonstrated delayed gastric emptying
  • Presence of moderate to severe nausea
  • (BMI) of ≥18 and ≤40 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis
  • A positive test for drugs of abuse at the screening or evaluation visits
  • Pregnancy or nursing
  • Evidence of uncontrolled blood glucose (including >11% at screening or metabolic crisis in past 60 days)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Open Label Tradipitant

    Oral Capsule

    Drug: Tradipitant

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs), including suicidal ideation or behavior as measured by the C-SSRS

    AEs will be coded using the MedDRA coding dictionary. An AE is defined as any untoward medical occurrence in a clinical investigation subject that does not necessarily have causal relationship with treatment. AEs will further be categorized by severity, relationship to study medication, and action taken. All AEs will be presented in data listings for subjects. The Columbia-Suicide Severity Rating Scale (C-SSRS) is a semi-structured clinical interview designed to systematically assess and track suicidal adverse events (behavior and ideation) throughout different settings including clinical trials. Results from the C-SSRS will be listed for each subject. These data will also be summarized for all subjects for suicidal ideation events, suicidal behaviors, and completed suicides.

    Time frame: 12 weeks

  2. Number of participants with changes in vital signs identified as Clinically Notable Abnormal values

    Vital sign measurements include oral temperature (C), respiratory rate, semi-supine blood pressure (systolic and diastolic) (mmHg) and semi-supine heart rate (bpm). Criteria for identifying vital signs as Potentially Clinically Notable Abnormalities are based on the Guidelines for the Division of Neuropharmacological Drug Products. Data from vital signs will be listed, clinically notable values will be flagged, and other information collected will be listed. Data will also be summarized using mean change from first study visit and proportion of subjects with values outside the normal range, and values that were clinically notable.

    Time frame: 12 weeks

  3. Number of participants with abnormal and potentially Clinically Notable Abnormal Electrocardiogram Intervals and Heart Rate

    Variables include PR (ms), QRS (ms), QTc (ms), and Heart Rate (bpm). Note: ms = millisecond; bpm = beats per minute

    Time frame: 12 weeks

  4. Number of participants with Clinically Notable Abnormal laboratory values

    Laboratory data will be summarized by presenting the proportions of patients with clinically notable abnormalities as follows: shift tables, first study visit to most extreme post-treatment value, using normal ranges; summary statistics of raw data and change from first study visit values (means, medians, standard deviations, ranges). Criteria for identifying laboratory values as Potentially Clinically Notable Abnormalities are based on the FDA's Guidelines for the Division of Neuropharmacological Drug Products.

    Time frame: 12 weeks

Secondary outcomes

  1. To evaluate the efficacy of tradipitant in reducing individual symptoms associated with gastroparesis

    Efficacy is assessed by the Gastroparesis Core Symptom Daily Diary (GCSDD). The GCSDD is a daily symptom diary asking patients to rate their nausea on a Likert scale from 0-5 (0=none, 5= very severe). Other symptoms include vomiting, postprandial fullness, early satiety, and abdominal pain.

    Time frame: 12 weeks

  2. To evaluate the efficacy of tradipitant in global improvement

    Efficacy is assessed by the Clinical Global Impression - Severity (CGI-S). The CGI-S is a clinician reported outcome that measures the clinician's view of the patient's global functioning prior to and after initiating treatment. Symptom severity is measured on a 7 point scale including "1=normal, not at all ill" and "7=among the most extremely ill patients."

    Time frame: 12 weeks

07

Study locations

3 sites
  • Vanda Investigational Site
    Leuven, 3000, Belgium
  • Vanda Investigational Site
    Liège, 4000, Belgium
  • Vanda Investigational Site
    Leipzig, 04103, Germany
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2024 to primary completion in Mar 2026, 26 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Dec 2025 → Mar 2026 and completion Dec 2025 → Mar 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2024
First posted
Feb 20, 2025
StartActual
Jan 9, 2024
Primary completionActual
Mar 30, 2026was Dec 2025
CompletionActual
Mar 30, 2026was Dec 2025
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 19, 2026
Primary completion
Dec 2025→Mar 30, 2026 (actual)
Oct 19, 2026
Study completion
Dec 2025→Mar 30, 2026 (actual)
Oct 19, 2026
Enrollment
100 (estimated)→17 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Recruiting→Completed
    Primary completion Dec 2025→Mar 30, 2026 (now actual)
    Study completion Dec 2025→Mar 30, 2026 (now actual)
    Enrollment 100 (estimated)→17 (actual)
    + 7 other changes: index terms, identifiers, verification date, oversight details, contact details, site details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06836557
Responsible party
Sponsor
First posted
Feb 20, 2025
Start date
Jan 9, 2024
Primary completion
Mar 30, 2026
Completion
Mar 30, 2026
Last update
Oct 19, 2026

Study contacts

Vanda Pharmaceuticals
study director · Vanda Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tradipitant

Start the discussion